Whether a new cough belongs among possible GLP-1 side effects depends on more than when it started. A U.S. electronic health record study matched 617,296 adults with obesity who started one of these drugs to an equal number of adults with obesity who did not use one. Matching accounted for age, sex, race and ethnicity [1].
How much more common was a recorded cough?
By six months, 2.36% of people in the treatment group and 1.63% of controls had a cough diagnosis in their records. The difference was 0.73 percentage points (95% CI 0.68 to 0.79). The odds ratio was 1.46 (95% CI 1.42 to 1.50). These are diagnoses documented in medical records, and the study cannot show how many patients had a cough they never reported.
The broader group of voice box and airway symptoms also had higher odds at six months (OR 1.19, 95% CI 1.16 to 1.21). The study’s drug-by-drug comparisons used this broader outcome, so they cannot tell us which medication is most likely to be associated with cough.
Could reflux explain the cough?
The pooled trial evidence on reflux suggests about four additional cases of gastroesophageal reflux disease per 1,000 people treated versus placebo (95% CI two to seven). The pooled risk ratio was 2.19 (95% CI 1.48 to 3.25)[2]. The trials measured reflux disease as a separate outcome.
In the medical record study, people with a reflux diagnosis had higher odds of a voice box or airway symptom whether or not they used a GLP-1 drug [1]. That pattern leaves reflux as a possible explanation, but it does not show that a medication triggered reflux and then cough.
What if a cough persists?
Tell your prescriber when the cough started and if you also noticed hoarseness or reflux symptoms. A clinician can consider the timing alongside other possible causes.